PEPGEN INC. Financing Cash Flow
PEPGEN INC. (PEPG) reported Financing Cash Flow of $1.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- PEPGEN INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$65.00K, a 166.33% decline year-over-year.
- PEPGEN INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $1.52M.
- PEPGEN INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$171.00K, a 233.59% decline year-over-year.
- PEPGEN INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $108.05M, a 32943.43% increase year-over-year.
- PEPGEN INC. net cash provided by (used in) financing activities for fiscal 2025 was $107.98M, a 21.67% increase from fiscal 2024.
- PEPGEN INC. net cash provided by (used in) financing activities for fiscal 2024 was $88.75M.
- PEPGEN INC. net cash provided by (used in) financing activities for fiscal 2023 was -$189.00K, a 100.17% decline from fiscal 2022.
- PEPGEN INC. net cash provided by (used in) financing activities for fiscal 2022 was $112.19M, a 24.02% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$65.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.45M 10-Q · filed 2026-08-06 | $1.28M derived: sum of 3 quarters · filed 2026-08-06 | $109.33M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $1.52M 10-Q · filed 2026-05-12 | $1.35M derived: sum of 2 quarters · filed 2026-05-12 | $109.40M derived: sum of 3 quarters · filed 2026-05-12 | $109.50M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$171.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $107.88M derived: sum of 2 quarters · filed 2026-03-04 | $107.98M derived: sum of 3 quarters · filed 2026-08-06 | $107.98M 10-K · filed 2026-03-04 | |
| 2025-09-30 | $108.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $108.15M derived: sum of 2 quarters · filed 2026-08-06 | $108.15M 10-Q · filed 2025-11-12 | $108.28M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $98.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $98.00K 10-Q · filed 2026-08-06 | $226.00K derived: sum of 3 quarters · filed 2026-08-06 | $553.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-12 | $128.00K derived: sum of 2 quarters · filed 2026-05-12 | $455.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.78M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $128.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $455.00K derived: sum of 2 quarters · filed 2026-03-04 | $1.78M derived: sum of 3 quarters · filed 2026-03-04 | $88.75M 10-K · filed 2026-03-04 | |
| 2024-09-30 | $327.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.65M derived: sum of 2 quarters · filed 2025-11-12 | $88.62M 10-Q · filed 2025-11-12 | $88.65M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $88.29M 10-Q · filed 2025-08-07 | $88.32M derived: sum of 3 quarters · filed 2025-08-07 | $87.99M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $86.97M 10-Q · filed 2025-05-08 | $86.99M derived: sum of 2 quarters · filed 2025-05-08 | $86.67M derived: sum of 3 quarters · filed 2025-05-08 | $86.65M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | -$300.00K derived: sum of 2 quarters · filed 2025-02-24 | -$319.00K derived: sum of 3 quarters · filed 2025-02-24 | -$189.00K 10-K · filed 2025-02-24 | |
| 2023-09-30 | -$326.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$345.00K derived: sum of 2 quarters · filed 2024-11-07 | -$215.00K 10-Q · filed 2024-11-07 | $2.00K derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $111.00K 10-Q · filed 2024-08-08 | $319.00K 10-Q · filed 2023-08-08 | $328.00K derived: sum of 3 quarters · filed 2024-08-08 | -$1.09M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $130.00K 10-Q · filed 2024-05-14 | $347.00K derived: sum of 2 quarters · filed 2024-05-14 | -$1.07M derived: sum of 3 quarters · filed 2024-05-14 | $112.34M derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | $217.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-29 | -$1.20M derived: sum of 2 quarters · filed 2024-03-29 | $112.21M derived: sum of 3 quarters · filed 2024-03-29 | $112.19M 10-K/A · filed 2024-03-29 | |
| 2022-09-30 | -$1.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $111.99M derived: sum of 2 quarters · filed 2023-11-08 | $111.98M 10-Q · filed 2023-11-08 | $110.95M derived: sum of 4 quarters · filed 2023-11-08 | |
| 2022-06-30 | $113.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $113.40M 10-Q · filed 2023-08-08 | $112.37M derived: sum of 3 quarters · filed 2023-08-08 | $245.24M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | -$18.00K 10-Q · filed 2023-05-11 | -$1.04M derived: sum of 2 quarters · filed 2023-05-11 | $131.82M derived: sum of 3 quarters · filed 2023-05-11 | ||
| 2021-12-31 | -$1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $131.84M derived: sum of 2 quarters · filed 2023-03-23 | $147.66M 10-K · filed 2023-03-23 | ||
| 2021-09-30 | $132.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $148.68M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $15.81M 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |